PolyPid Ltd.(PYPD)Earnings, Financials & Key Ratios
PYPD•NASDAQ
$5.33
Price updated Jul 7, 2026
AboutPolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Show more
- Revenue$0
- EBITDA-$31M-18.7%
- Net Income-$34M-17.7%
- EPS (Diluted)-2.09+57.4%
- ROE-366.29%+64.7%
PYPD Price & Volume
PolyPid Ltd. (PYPD) stock price & volume — 10-year historical chart
Loading chart...
Clinical Trial Dependency Drives Persistent Capital Erosion
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial dependency
Key Thesis Takeaways
- PolyPid remains a high-risk, binary-outcome biotechnology entity entirely dependent on the successful execution of its SHIELD II Phase III clinical trial.
- The firm lacks any commercial revenue stream, resulting in a persistent reliance on external financing to cover R&D expenses that reached $6.2 million in 2025Q4.
- Investors should monitor the company's narrowing liquidity runway, as the current cash position of $6.4 million may necessitate further dilutive capital raises to sustain operations.
Verdict Logic
the company's reliance on external capital to fund its $8.5 million quarterly net loss, combined with a dwindling $6.4 million cash balance, presents an unsustainable risk profile for long-term investors.
PYPD Growth Metrics
PolyPid Ltd. (PYPD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-43.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.97%
Return on Capital
10 Years-136.43%
5 Years-183.72%
3 Years-231.45%
Last Year-243.24%
PYPD Recent Earnings
PolyPid Ltd. (PYPD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.35+25.5%
$0.47
Rev
—
—
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$0.41-20.6%
$0.34
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.37+31.5%
$0.54
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.78-47.2%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.35vs $0.47+25.5% | — |
| Q1 2026 | Feb 11, 2026 | $0.41vs $0.34-20.6% | — |
| Q4 2025 | Nov 12, 2025 | $0.37vs $0.54+31.5% | — |
| Q3 2025 | Aug 13, 2025 | $0.78vs $0.53-47.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PolyPid Ltd. (PYPD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.33 | $54.32M | -2.55 | — | — | -366.29% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $5.62 | $677.74M | -10.60 | -58.19% | -832.58% | -55.89% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — |
Compare PYPD vs Peers
PolyPid Ltd. (PYPD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PYPD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PYPD Frequently Asked Questions
PolyPid Ltd. (PYPD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PYPD profitable?
PolyPid Ltd. (PYPD) reported a net loss of $34.2M for fiscal year 2025.
Dividend & Returns
What is PYPD's return on equity?
PolyPid Ltd. (PYPD) has a return on equity (ROE) of -366.3%. Negative ROE indicates the company is unprofitable.